Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H18O12 |
Molecular Weight | 462.3612 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
c1cc(ccc1-c2cc(=O)c3c(cc(c(c3O)O)O[C@@]4([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C(=O)O)O4)O)O)O)o2)O
InChI
InChIKey=DJSISFGPUUYILV-ZFORQUDYSA-N
InChI=1S/C21H18O12/c22-8-3-1-7(2-4-8)10-5-9(23)13-11(31-10)6-12(14(24)15(13)25)32-21-18(28)16(26)17(27)19(33-21)20(29)30/h1-6,16-19,21-22,24-28H,(H,29,30)/t16-,17-,18+,19-,21+/m0/s1
Molecular Formula | C21H18O12 |
Molecular Weight | 462.3612 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Scutellarin is the main bioactive component of Breviscapine prepared from the traditional Chinese herb Erilgeron breviscapus (Vant) Hand-Mazz. Scutellarin demonstrated protective effect on cardiovascular and cerebrovascular ischemia. The potential cytoprotective effects of the drug against cerebrovascular ischemia were evidenced by reducing cerebral infarct sizes, ameliorating neurological deficit and inhibiting neuronal apoptosis. Scutellarin is capable of inhibiting I(Na) in neurons through predominantly affecting the inactivated state of I(Na). Scutellarin may alleviate cognitive impairment in a mouse model of hypoxia by promoting proliferation and neuronal differentiation of neural stem cells. Scutellarin might play an therapeutic role by inhibiting oxidative stress and apoptosis in Alzheimer's disease treatment.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Sodium channels Sources: https://www.ncbi.nlm.nih.gov/pubmed/21340731 |
7.1 µM [Ki] | ||
Target ID: map04210 |
|||
Target ID: CHEMBL3199 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21986571 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16714374
Single administration of 60 mg of scutellarin.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19661313
100 uM of scutellarin sensitized resveratrol (200 uM) and 5-fluorouracil (500 uM)-evoked apoptosis in p53+/+ but not p53(-/-) cells. Resveratrol- and 5-fluorouracil-elicited caspase-6 activation were promoted by scutellarin in a time-dependent manner. scutellarin itself did not trigger apoptosis or caspase-6 activation at the concentration tested.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Jun 26 14:15:11 UTC 2021
by
admin
on
Sat Jun 26 14:15:11 UTC 2021
|
Record UNII |
16IGP0ML9A
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
M9819
Created by
admin on Sat Jun 26 14:15:12 UTC 2021 , Edited by admin on Sat Jun 26 14:15:12 UTC 2021
|
PRIMARY | |||
|
SUB130603
Created by
admin on Sat Jun 26 14:15:12 UTC 2021 , Edited by admin on Sat Jun 26 14:15:12 UTC 2021
|
PRIMARY | |||
|
1692861-25-8
Created by
admin on Sat Jun 26 14:15:12 UTC 2021 , Edited by admin on Sat Jun 26 14:15:12 UTC 2021
|
SUPERSEDED | |||
|
16IGP0ML9A
Created by
admin on Sat Jun 26 14:15:12 UTC 2021 , Edited by admin on Sat Jun 26 14:15:12 UTC 2021
|
PRIMARY | |||
|
1329-06-2
Created by
admin on Sat Jun 26 14:15:12 UTC 2021 , Edited by admin on Sat Jun 26 14:15:12 UTC 2021
|
SUPERSEDED | |||
|
27740-01-8
Created by
admin on Sat Jun 26 14:15:12 UTC 2021 , Edited by admin on Sat Jun 26 14:15:12 UTC 2021
|
PRIMARY | |||
|
Scutellarin
Created by
admin on Sat Jun 26 14:15:12 UTC 2021 , Edited by admin on Sat Jun 26 14:15:12 UTC 2021
|
PRIMARY | |||
|
32647-60-2
Created by
admin on Sat Jun 26 14:15:12 UTC 2021 , Edited by admin on Sat Jun 26 14:15:12 UTC 2021
|
SUPERSEDED | |||
|
676536-34-8
Created by
admin on Sat Jun 26 14:15:12 UTC 2021 , Edited by admin on Sat Jun 26 14:15:12 UTC 2021
|
SUPERSEDED | |||
|
185617
Created by
admin on Sat Jun 26 14:15:12 UTC 2021 , Edited by admin on Sat Jun 26 14:15:12 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> SUBSTRATE | |||
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
TRANSPORTER -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
TRANSPORTER -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
MAJOR
PLASMA; URINE
|
||
|
METABOLITE -> PARENT |
MAJOR
URINE
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Tmax | PHARMACOKINETIC |
|
SINGLE ORAL ADMINISTRATION |
|
||
Biological Half-life | PHARMACOKINETIC |
|
SINGLE ORAL ADMINISTRATION |
|
||